Second-generation incretin therapies causing substantial weight loss may lead to micronutrient deficiencies through reduced food intake and malabsorption, requiring proactive nutritional monitoring.
Hidden deficienciesMillions on GLP-1 drugs eat 15-25%+ less but rarely get nutritional monitoring — micronutrient deficiencies may be developing undetected
What the researchers found
Second-generation incretin therapies risk micronutrient deficiencies (B12, D, iron, folate) through reduced intake and potential malabsorption, requiring proactive monitoring not currently standard in GLP-1 prescribing.
Why it matters
Micronutrient deficiencies cause anemia, neuropathy, bone loss, and immune dysfunction. Millions on GLP-1 drugs may be developing deficiencies without monitoring.
How the study worked
Review of micronutrient deficiency risks associated with substantial weight loss from second-generation incretin-based therapies.
What this study cannot tell us
Review. Actual deficiency prevalence in GLP-1 users not well-quantified. Individual risk varies.
How to read the evidence
Review raising awareness of under-recognized risk.
When this study was published
Published in 2025.
The bigger picture
The GLP-1 drug revolution needs a nutritional safety net — systematic monitoring that bariatric surgery already provides.
Questions still open
- Should all GLP-1 drug users take a multivitamin?
- Which specific deficiencies are most common with incretin therapy?
- Should nutritional monitoring be required for GLP-1 prescriptions?
Common questions
Should I take vitamins while on GLP-1 drugs?
Why don't doctors check for this?
Read the original research
Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.
Nutrients, 18(4)
Citation
Koceva, Andrijana; Janež, Andrej; Pečko, Tajda; Jensterle, Mojca. (2026). Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.. Nutrients, 18(4). https://doi.org/10.3390/nu18040677